The impact of past COVID-19 infection on pregnancy rates in frozen embryo transfer cycles

Michal Youngster, Sarit Avraham, Odelia Yaakov, Moran Landau Rabbi, Itai Gat, Gil Yerushalmi, Micha Baum, Ettie Maman, Ariel Hourvitz, Alon Kedem, Michal Youngster, Sarit Avraham, Odelia Yaakov, Moran Landau Rabbi, Itai Gat, Gil Yerushalmi, Micha Baum, Ettie Maman, Ariel Hourvitz, Alon Kedem

Abstract

Purpose: To study the effect of SARS-CoV-2 infection on pregnancy rates in frozen embryo transfer (FET) cycles.

Methods: A retrospective cohort study including women under the age of 42 with documented SARS-CoV-2 infection up to 1 year prior to treatment, undergoing FET cycles in the first half of 2021, with transfer of embryos generated prior to the infection. Controls were SARS-CoV-2 non-diagnosed, non-vaccinated women matched by age, number, and day of embryo transfer. Demographic and cycle characteristics and outcomes were compared.

Results: Forty-one recovered women and 41 controls were included. Pregnancy rates were 29% and 49% respectively (p = 0.070). Stratification by time from SARS-CoV-2 infection to transfer into ≤ 60 and > 60 days revealed a difference in pregnancy rates, with women in the COVID group having lower pregnancy rates if infected in proximity to the transfer (21% vs. 55%; p = 0.006). In a logistic regression model, infection was a significant variable (p = 0.05, OR 0.325, 95% CI 0.106-0.998). Logistic regression applied on the subgroup of women infected in proximity to the transfer further strengthened the univariate results, with COVID-19 remaining a significant parameter (p = 0.005, OR 0.072, 95% CI 0.012-0.450).

Conclusions: In FET cycles of patients with past SARS-CoV-2 infection, in which oocytes were retrieved prior to infection, decreased pregnancy rates were observed, specifically in patients who recovered less than 60 days prior to embryo transfer. Pending further studies, in cases of FET cycles with limited number of embryos, postponing embryo transfer for at least 60 days following recovery from COVID-19 might be considered when feasible.

Keywords: COVID-19; FET; Pregnancy; SARS-CoV-2.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

References

    1. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114.
    1. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med [Internet]. 2020 [cited 2021 Oct 16];14:185–92. 10.1007/s11684-020-0754-0.
    1. Guo L, Zhao S, Li W, Wang Y, Li L, Jiang S, et al. Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort. Andrology. 2021;9:42–7. doi: 10.1111/andr.12848.
    1. Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Network Open. 2020;3:e208292.
    1. Gacci M, Coppi M, Baldi E, Sebastianelli A, Zaccaro C, Morselli S et al. Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19. Hum Reprod [Internet]. Oxford Academic; 2021 [cited 2021 Oct 16];36:1520–9. Available from: .
    1. Tur-Kaspa I, Tur-Kaspa T, Hildebrand G, Cohen D. COVID-19 may affect male fertility but is not sexually transmitted: a systematic review. F&S Rev Elsevier. 2021;2:140–149. doi: 10.1016/j.xfnr.2021.01.002.
    1. Anifandis G, Messini CI, Daponte A, Messinis IE. COVID-19 and fertility: a virtual reality. Reprod Biomed Online [Internet] 2020;41:157–9. doi: 10.1016/j.rbmo.2020.05.001.
    1. Li R, Yin T, Fang F, Li Q, Chen J, Wang Y et al. Potential risks of SARS-CoV-2 infection on reproductive health [Internet]. Reprod Biomed. Online. 2020 [cited 2021 Sep 8]. p. 89–95. 10.1016/j.rbmo.2020.04.018.
    1. Reis FM, Bouissou DR, Pereira VM, Camargos AF, Dos Reis AM, Santos RA. Angiotensin-(1–7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 2011;95:176–181. doi: 10.1016/j.fertnstert.2010.06.060.
    1. Anifandis G, Messini CI, Simopoulou M, Sveronis G, Garas A, Daponte A et al. SARS-CoV-2 vs. human gametes, embryos and cryopreservation. Syst Biol Reprod Med [Internet]. 2021;67:260–9.
    1. Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G et al. Potential influence of COVID-19/ACE2 on the female reproductive system. Mol Hum Reprod [Internet]. 2020;26:367–73.
    1. Choi Y, Jeon H, Brännström M, Akin JW, Curry TE, Jo M. Ovulatory upregulation of angiotensin-converting enzyme 2, a receptor for SARS-CoV-2, in dominant follicles of the human ovary. Fertil Steril [Internet]. Fertil Steril; 2021 [cited 2021 Dec 1];116.
    1. Vaz-Silva J, Carneiro MM, Ferreira MC, Pinheiro SVB, Silva DA, Silva-Filho AL et al. The vasoactive peptide angiotensin-(1—7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium: 101177/1933719108327593 [Internet]. SAGE PublicationsSage CA: Los Angeles, CA; 2009 [cited 2021 Oct 16];16:247–56. Available from: 10.1177/1933719108327593.
    1. Henarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A, Pellicer A, Diaz-Gimeno P. SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle. Fertil Steril [Internet] 2020;114:223–232. doi: 10.1016/j.fertnstert.2020.06.026.
    1. Arechavaleta-Velasco F, Koi H, Strauss JF, Parry S. Viral infection of the trophoblast: time to take a serious look at its role in abnormal implantation and placentation? J Reprod Immunol [Internet]. 2002;55:113–21.
    1. Li K, Chen G, Hou H, Liao Q, Chen J, Bai H et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online [Internet]. 2021 [cited 2021 Dec 16];42:260–7. 10.1016/j.rbmo.2020.09.020.
    1. Balaban B, Brison D, Calderón G, Catt J, Conaghan J, Cowan L et al. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod [Internet]. Hum Reprod; 2011 [cited 2021 Oct 16]. p. 1270–83. Available from: .
    1. Aizer A, Noach-Hirsh M, Dratviman-Storobinsky O, Nahum R, Machtinger R, Yung Y et al. The effect of COVID-19 immunity on frozen-thawed embryo transfer cycles outcome. Fertil Steril [Internet]. 2022; Available from: .
    1. Chen L, Huang X, Yi Z, Deng Q, Jiang N, Feng C et al. Ultrasound imaging findings of acute testicular infection in patients with coronavirus disease 2019: a single-center-based study in Wuhan, China. J Ultrasound Med [Internet]. 2021;40:1787–94. Available from: .
    1. Garrido-Pontnou M, Navarro A, Camacho J, Crispi F, Alguacil-Guillén M, Moreno-Baró A et al. Diffuse trophoblast damage is the hallmark of SARS-CoV-2-associated fetal demise. Mod Pathol [Internet]. 2021;34:1704–9.
    1. Ganor Paz Y, Shiloh S, Brosh-Nissimov T, Grupel D, Sorek N, Kustin T, Stern A, Maklakovsky M, Polak M, Sharvit M, Neeman O, Ben Valid T, Tovbin J, Barzilay E. The association between SARS-CoV-2 infection and late pregnancy loss. Int J Gynaecol Obstet. 2022;157(1):208–9.
    1. Groenewoud ER, Cohlen BJ, Al-Oraiby A, Brinkhuis EA, Broekmans FJM, De Bruin JP et al. A randomized controlled, non-inferiority trial of modified natural versus artificial cycle for cryo-thawed embryo transfer. Hum Reprod. Hum Reprod; 2016 [cited 2022 Apr 12];31:1483–92. Available from: .

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner